A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

What Was Tested

The trial (phase 1) is built around Retatrutide.

The main purpose of this study is to learn about the side effects of LY3437943 when given to Japanese participants with type 2 diabetes mellitus.

Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin.

It had two arms (groups): LY3437943 (experimental) and Placebo (placebo comparator).

LY3437943 administered subcutaneously (SC).

Placebo administered SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 64 actual participants took part.

It was open to people of any sex aged from 20 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year. Have a body mass index (BMI) within the range 23 to 35 kilograms per square meter (kg/m²), inclusive, and a body weight of at least 54 kilograms (Kg). Males and females not of childbearing potential.

How the Study Was Run

It was run as a randomized, parallel-group and double-blind study.

The participants were allocated by chance, so the Retatrutide group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Retatrutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2021-05-24 with completion listed for 2022-06-23.

It ran at 4 sites in Japan (4).

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (time frame: Baseline through Day 106).

It also tracked 6 secondary outcomes, for example PK: Area Under the Concentration Versus Time Curve (AUC) of LY3437943, Change from Baseline in Mean Daily Plasma Glucose (PG), Change from Baseline in Glycated Hemoglobin (HbA1c), Change from Baseline in Fasting Glucose and Change from Baseline in Body Weight.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Retatrutide in 64 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Retatrutide compound page, all human trials.